Please try another search
On Friday, Morgan Stanley updated its outlook on MYT Netherlands (NYSE: MYTE), increasing the price target to $3.75 from $3.50, while maintaining an Equalweight rating. This adjustment follows...
MUNICH - MYT Netherlands Parent B.V. (NYSE: MYTE), known as Mytheresa, has announced preliminary unaudited financial results for its third quarter ending March 31, 2024, showcasing double-digit growth...
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18%Net Q4 2023 revenue of...
We are initiating research on Jaguar Health Inc (NASDAQ:JAGX), which is centered on the development and marketing of its drug crofelemer for diarrheal disorders. It is approved and marketed under the...
In May 2019, Redhill Biopharma Ltd (NASDAQ:RDHL) submitted an NDA for TALICIA for the treatment of H. pylori infection. If all goes according to plan, the drug could be launched by end-2019. This...
Instrument Type
Region
Sector
Industry
Date
Category
Provider